HUM:NYSEHumana Inc. Analysis

Humana (HUM) trades at $173.62, well below its DCF fair value of $300.43, implying roughly a 27% upside and a valuation grade of undervalued. The stock’s PE of 17.6 is markedly lower than the industry average of 25.2, reinforcing the value case. Revenue grew 11.3% YoY to $129.66 B, and forward EPS is projected at $15.69, indicating solid growth momentum. However, the technical picture is bearish: the price sits beneath the 20‑day (182.27), 50‑day (219.75) and 200‑day (248.26) SMAs, RSI is at 32.9 (near‑oversold), and the trend is flagged as bearish with decreasing volume. The MACD shows a modest bullish histogram (+1.71) but the line remains negative, suggesting limited short‑term upside. Recent Q4 2025 results missed earnings guidance and prompted an RBC downgrade, adding pressure to the stock. Despite these headwinds, the dividend yield of 1.98% with a 36% payout ratio appears sustainable given strong cash flow and a low beta of 0.32. Volatility is high at nearly 80% over 30 days, reflecting market uncertainty. The support level at $169.61 provides a near‑term floor, while resistance sits around $192.02. Overall, HUM presents a compelling value proposition with growth drivers, but investors must navigate short‑term technical weakness and regulatory uncertainty.
Long‑term investors may benefit from demographic tailwinds in Medicare Advantage, a stable dividend, and an attractive valuation gap. The modest debt‑to‑equity ratio (74.8) and ample cash position ($19.9 B) cushion financial risk, while the sector’s medium risk and low geographic exposure further support a positive outlook. Cautious positioning is advised until the stock stabilizes above key technical levels.